BACKGROUND AND PURPOSE: PDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle are unknown. We investigated whether the PDE3-selective inhibitor cilostamide (0.3-1 μM) or PDE4 inhibitor rolipram (1-10 μM) modified the positive inotropic and lusitropic effects of catecholamines in human failing myocardium. EXPERIMENTAL APPROACH: Right and left ventricular trabeculae from freshly explanted hearts of 5 non-β-blocker-treated and 15 metoprolol-treated patients with terminal heart failure were paced to contract at 1 Hz. The effects of (-)-noradrenaline, mediated through β₁ adrenoceptors (β₂ adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through β₂ adrenoceptors (β₁ adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of PDE inhibitors. Catecholamine potencies were estimated from -logEC₅₀s. KEY RESULTS: Cilostamide did not significantly potentiate the inotropic effects of the catecholamines in non-β-blocker-treated patients. Cilostamide caused greater potentiation (P = 0.037) of the positive inotropic effects of (-)-adrenaline (0.78 ± 0.12 log units) than (-)-noradrenaline (0.47 ± 0.12 log units) in metoprolol-treated patients. Lusitropic effects of the catecholamines were also potentiated by cilostamide. Rolipram did not affect the inotropic and lusitropic potencies of (-)-noradrenaline or (-)-adrenaline on right and left ventricular trabeculae from metoprolol-treated patients. CONCLUSIONS AND IMPLICATIONS: Metoprolol induces a control by PDE3 of ventricular effects mediated through both β₁ and β₂ adrenoceptors, thereby further reducing sympathetic cardiostimulation in patients with terminal heart failure. Concurrent therapy with a PDE3 blocker and metoprolol could conceivably facilitate cardiostimulation evoked by adrenaline through β₂ adrenoceptors. PDE4 does not appear to reduce inotropic and lusitropic effects of catecholamines in failing human ventricle.
BACKGROUND AND PURPOSE: PDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle are unknown. We investigated whether the PDE3-selective inhibitor cilostamide (0.3-1 μM) or PDE4 inhibitor rolipram (1-10 μM) modified the positive inotropic and lusitropic effects of catecholamines in human failing myocardium. EXPERIMENTAL APPROACH: Right and left ventricular trabeculae from freshly explanted hearts of 5 non-β-blocker-treated and 15 metoprolol-treated patients with terminal heart failure were paced to contract at 1 Hz. The effects of (-)-noradrenaline, mediated through β₁ adrenoceptors (β₂ adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through β₂ adrenoceptors (β₁ adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of PDE inhibitors. Catecholamine potencies were estimated from -logEC₅₀s. KEY RESULTS:Cilostamide did not significantly potentiate the inotropic effects of the catecholamines in non-β-blocker-treated patients. Cilostamide caused greater potentiation (P = 0.037) of the positive inotropic effects of (-)-adrenaline (0.78 ± 0.12 log units) than (-)-noradrenaline (0.47 ± 0.12 log units) in metoprolol-treated patients. Lusitropic effects of the catecholamines were also potentiated by cilostamide. Rolipram did not affect the inotropic and lusitropic potencies of (-)-noradrenaline or (-)-adrenaline on right and left ventricular trabeculae from metoprolol-treated patients. CONCLUSIONS AND IMPLICATIONS: Metoprolol induces a control by PDE3 of ventricular effects mediated through both β₁ and β₂ adrenoceptors, thereby further reducing sympathetic cardiostimulation in patients with terminal heart failure. Concurrent therapy with a PDE3 blocker and metoprolol could conceivably facilitate cardiostimulation evoked by adrenaline through β₂ adrenoceptors. PDE4 does not appear to reduce inotropic and lusitropic effects of catecholamines in failing human ventricle.
Authors: S Bartel; B Stein; T Eschenhagen; U Mende; J Neumann; W Schmitz; E G Krause; P Karczewski; H Scholz Journal: Mol Cell Biochem Date: 1996 Apr 12-26 Impact factor: 3.396
Authors: H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1991-07 Impact factor: 3.000
Authors: Bo Ding; Jun-Ichi Abe; Heng Wei; Haodong Xu; Wenyi Che; Toru Aizawa; Weimin Liu; Carlos A Molina; Junichi Sadoshima; Burns C Blaxall; Bradford C Berk; Chen Yan Journal: Proc Natl Acad Sci U S A Date: 2005-09-26 Impact factor: 11.205
Authors: Stephan E Lehnart; Xander H T Wehrens; Steven Reiken; Sunita Warrier; Andriy E Belevych; Robert D Harvey; Wito Richter; S-L Catherine Jin; Marco Conti; Andrew R Marks Journal: Cell Date: 2005-10-07 Impact factor: 41.582
Authors: Bo Ding; Jun-Ichi Abe; Heng Wei; Qunhua Huang; Richard A Walsh; Carlos A Molina; Allan Zhao; Junichi Sadoshima; Burns C Blaxall; Bradford C Berk; Chen Yan Journal: Circulation Date: 2005-05-02 Impact factor: 29.690
Authors: M Sigmund; H Jakob; H Becker; P Hanrath; C Schumacher; T Eschenhagen; W Schmitz; H Scholz; M Steinfath Journal: Eur J Clin Pharmacol Date: 1996 Impact factor: 2.953
Authors: T Eschenhagen; U Mende; M Diederich; M Nose; W Schmitz; H Scholz; J Schulte am Esch; A Warnholtz; H Schäfer Journal: Mol Pharmacol Date: 1992-11 Impact factor: 4.436
Authors: A Kaumann; S Bartel; P Molenaar; L Sanders; K Burrell; D Vetter; P Hempel; P Karczewski; E G Krause Journal: Circulation Date: 1999 Jan 5-12 Impact factor: 29.690
Authors: Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello Journal: Nat Rev Drug Discov Date: 2014-04 Impact factor: 84.694
Authors: Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis Journal: Endocr Rev Date: 2013-12-05 Impact factor: 19.871
Authors: Caroline Bull Melsom; Rizwan Iqbal Hussain; Øivind Ørstavik; Jan Magnus Aronsen; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-09-13 Impact factor: 3.000
Authors: Regina Celia Spadari; Claudia Cavadas; Ana Elisa T Saturi de Carvalho; Daniela Ortolani; Andre Luiz de Moura; Paula Frizera Vassalo Journal: Cell Mol Neurobiol Date: 2017-10-24 Impact factor: 5.046